Joseph Kendra

Joseph Kendra


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Reviews in Medical Virology
Verified
Journal Article
Open access
JKJoseph A. Kendra
Joseph A. Kendra
KTKentaro Tohma
Kentaro Tohma
GPGabriel Parra
Gabriel Parra
Human noroviruses are the leading global cause of viral gastroenteritis. Attempts at developing effective vaccines and treatments against norovirus disease have been stymied by the extreme genetic diversity and rapid geographic distribution of these viruses. The emergence and replacement of predominantly circulating norovirus genotypes has primarily been attributed to mutations on the VP1 capsid protein leading to genetic drift, and more recently to recombination events between the ORF1/ORF2 junction. However, large‐scale research into the historical and geographic distribution of recombinant norovirus strains has been limited in the literature. We performed a comprehensive historical analysis on 30,810 human norovirus sequences submitted to public databases between the years 1995 and 2019. During this time, 37 capsid genotypes and 56 polymerase types were detected across 90 different countries, and 97 unique recombinant genomes were also identified. GII.4, both capsid and polymerase, was the predominately circulating type worldwide for the majority of this time span, save for a brief swell of GII.17 and GII.2 capsid genotypes and a near‐total eclipse by GII.P16, GII.P21 and GII.P31 beginning in 2013. Interestingly, an analysis of 4067 recombinants found that 50.2% (N = 2039) of all recorded sequences belonged to three recently emerged recombinant strains: GII.2[P16], GII.4[P31], and GII.4[P16]. This analysis should provide an important historical foundation for future studies that evaluate the emergence and distribution of noroviruses, as well as the design of cross‐protective vaccines.

8 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JKJoseph A. Kendra
Joseph A. Kendra
KTKentaro Tohma
Kentaro Tohma
LSLauren A. Siltz
Lauren A. Siltz
CLCara Lepore
Cara Lepore
GPGabriel Parra
Gabriel Parra
Significance: The GII.4 genotype of human noroviruses accounts for the majority of gastroenteritis outbreaks worldwide. This predominance is characterized by the chronological emergence of new variants in response to immune pressure. We performed a comprehensive analysis on a large panel of GII.4 viruses to investigate the genetic determinants of antigenic diversification. Using immunoassays and neutralization data, we observed major changes to antigenic properties over the course of GII.4 evolution and increased intervariant cross-reactivity across contemporary viruses. Antigenic cartography and sequence analyses indicated a minimum number of coevolving amino acid changes on the structural protein necessary for the emergence of antigenically distinct variants. These insights could facilitate the monitoring and characterization of emerging GII.4 noroviruses and the development of cross-protective vaccines.

1 February 2017 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JKJoseph A. Kendra
Joseph A. Kendra
CFCynthia de la Fuente
Cynthia de la Fuente
ABAshwini Brahms
Ashwini Brahms
CWCaitlin Woodson
Caitlin Woodson
TBTodd M. Bell
Todd M. Bell
Jonathan DinmanJonathan Dinman
Jonathan Dinman
The alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) are arthropod-borne positive-strand RNA viruses that are capable of causing acute and fatal encephalitis in many mammals, including humans. VEEV was weaponized during the Cold War and is recognized as a select agent. Currently, there are no FDA-approved vaccines or therapeutics for these viruses. The spread of VEEV and other members of this family due to climate change-mediated vector range expansion underscores the need for research aimed at developing medical countermeasures. These viruses utilize programmed −1 ribosomal frameshifting (−1 PRF) to synthesize the viral trans -frame (TF) protein, which has previously been shown to be important for neuropathogenesis in the related Sindbis virus. Here, the alphavirus −1 PRF signals were characterized, revealing novel −1 PRF stimulatory structures. −1 PRF attenuation mildly affected the kinetics of VEEV accumulation in cultured cells but strongly inhibited its pathogenesis in an aerosol infection mouse model. Importantly, the decreased viral titers in the brains of mice infected with the mutant virus suggest that the alphavirus TF protein is important for passage through the blood-brain barrier and/or for neuroinvasiveness. These findings suggest a novel approach to the development of safe and effective live attenuated vaccines directed against VEEV and perhaps other closely related −1 PRF-utilizing viruses. IMPORTANCE Venezuelan equine encephalitis virus (VEEV) is a select agent that has been weaponized. This arthropod-borne positive-strand RNA virus causes acute and fatal encephalitis in many mammals, including humans. There is no vaccine or other approved therapeutic. VEEV and related alphaviruses utilize programmed −1 ribosomal frameshifting (−1 PRF) to synthesize the viral trans -frame (TF) protein, which is important for neuropathogenesis. −1 PRF attenuation strongly inhibited VEEV pathogenesis in mice, and viral replication analyses suggest that the TF protein is critical for neurological disease. These findings suggest a new approach to the development of safe and effective live attenuated vaccines directed against VEEV and other related viruses.

24 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KTKentaro Tohma
Kentaro Tohma
SJSonja Jacobsen
Sonja Jacobsen
BABritta Altmann
Britta Altmann
JKJoseph A. Kendra
Joseph A. Kendra
MLMichael Landivar
Michael Landivar
GPGabriel Parra
Gabriel Parra
Over the past two years, increased norovirus activity has been reported in multiple countries, accompanied by a rise in genotype GII.17 prevalence. Despite causing large outbreaks in Asia during 2014-2016, GII.17 has not historically been considered a predominant genotype. In this study, using 1471 archival and newly-identified GII.17 genomes, we investigated (i) global diversification patterns of this virus at the whole-genome level, (ii) in-depth mutational patterns within 511 viruses detected during a 10-year national survey in Germany, and (iii) intra-host viral diversity and adaptation processes that lead to the predominance of the GII.17 virus. The recent GII.17 norovirus exhibited extensive genetic diversity and multiple back-and-forth and recurrent mutations during the early phase of its epidemic; however, this diversity declined by 2024, suggesting that the virus had reached a phenotype efficient for human infection. Experimental data confirmed that mutations in the viral capsid enhanced binding to host factors associated with virus entry and resulted in antigenic changes compared to previously circulating clusters. Overall, this study demonstrated that the recent surge of GII.17 resulted from a dynamic, multifaceted process involving diverse adaptive strategies, ultimately enabling the virus to achieve sustained transmission within the human population.

1 November 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JKJoseph A. Kendra
Joseph A. Kendra
VAVivek M. Advani
Vivek M. Advani
BCBin Chen
Bin Chen
JBJoseph W. Briggs
Joseph W. Briggs
JZJinyi Zhu
Jinyi Zhu
Jonathan DinmanJonathan Dinman
Jonathan Dinman
Climate change and human globalization have spurred the rapid spread of mosquito-borne diseases to naïve populations. One such emerging virus of public health concern is Chikungunya virus (CHIKV), a member of the Togaviridae family, genus alphavirus. CHIKV pathogenesis is predominately characterized by acute febrile symptoms and severe arthralgia, which can persist in the host long after viral clearance. CHIKV has also been implicated in cases of acute encephalomyelitis, and its vertical transmission has been reported. Currently, no FDA-approved treatments exist for this virus. Recoding elements help expand the coding capacity in many viruses and therefore represent potential therapeutic targets in antiviral treatments. Here, we report the molecular and structural characterization of two CHIKV translational recoding signals: a termination codon read-through (TCR) element located between the nonstructural protein 3 and 4 genes and a programmed -1 ribosomal frameshift (-1 PRF) signal located toward the 3′ end of the CHIKV 6K gene. Using dual-luciferase and immunoblot assays in HEK293T and U87MG mammalian cell lines, we validated and genetically characterized efficient TCR and -1 PRF. Analyses of RNA chemical modification data with selective 2′-hydroxyl acylation and primer extension (SHAPE) assays revealed that CHIKV-1 PRF is stimulated by a tightly structured, triple-stem hairpin element, consistent with previous observations in alphaviruses, and that the TCR signal is composed of a single large multi-bulged hairpin element. These findings illuminate the roles of RNA structure in translational recoding and provide critical information relevant for design of live-attenuated vaccines against CHIKV and related viruses.

6 June 2025 in Journal of General Virology
Verified
Journal Article
Open access
GPGabriel Parra
Gabriel Parra
KTKentaro Tohma
Kentaro Tohma
LSLauren A. Siltz
Lauren A. Siltz
KPKelsey Pilewski
Kelsey Pilewski
JKJoseph Kendra
Joseph Kendra
Norovirus is a major cause of acute gastroenteritis in all age groups, with recent surges of cases in Europe and the USA reinforcing the influence of this virus on human health. Despite its societal impact, no vaccine or antiviral drug is available. The development of these countermeasures has been impaired at least in part by the extreme genetic and antigenic diversity of noroviruses. Here, we reviewed historical norovirus outbreaks, including the pandemics of GII.4 norovirus that were first documented in the mid-1990s, sporadic increases of non-GII.4 norovirus (e.g. GII.17 and GII.2) during the 2010s and, most recently, the ongoing large outbreaks caused by a new cluster of GII.17 noroviruses. This five-decade-long journey of tracking noroviruses in the human population illustrates the importance and challenges of battling this evolving virus.